Helen I. Torley

2020

In 2020, Helen I. Torley earned a total compensation of $6.5M as President and Chief Executive Officer at Halozyme Therapeutics, a 11% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$712,270
Option Awards$2,500,001
Salary$791,440
Stock Awards$2,500,018
Other$15,147
Total$6,518,876

Torley received $2.5M in stock awards, accounting for 38% of the total pay in 2020.

Torley also received $712.3K in non-equity incentive plan, $2.5M in option awards, $791.4K in salary and $15.1K in other compensation.

Rankings

In 2020, Helen I. Torley's compensation ranked 1,541st out of 13,090 executives tracked by ExecPay. In other words, Torley earned more than 88.2% of executives.

ClassificationRankingPercentile
All
1,541
out of 13,090
88th
Division
Manufacturing
575
out of 5,621
90th
Major group
Chemicals And Allied Products
209
out of 2,254
91st
Industry group
Drugs
175
out of 1,954
91st
Industry
Biological Products, Except Diagnostic Substances
54
out of 411
87th

Pay ratio

Helen I. Torley's Pay$6,518,876
Median Employee's Pay$223,441
Pay Ratio

29

to 1

In 2020, the annual total compensation of Helen I. Torley was $6,518,876.

The annual total compensation of the median employee at Halozyme Therapeutics was $223,441.

The ratio of Helen I. Torley's pay to the pay of median employee was therefore 29 to one.

Source: SEC filing on March 26, 2021.

Torley's colleagues

We found four more compensation records of executives who worked with Helen I. Torley at Halozyme Therapeutics in 2020.

2020

Elaine Sun

Halozyme Therapeutics

Chief Financial Officer

2020

Michael LaBarre

Halozyme Therapeutics

Senior Vice President, Chief Technical Officer

2020

Masaru Matsuda

Halozyme Therapeutics

General Counsel

2020

Laurie Stelzer

Halozyme Therapeutics

Chief Financial Officer

News

You may also like